68 CHAPTER 5 TABLE 1: BASELINE CHARACTERISTICS OF PATIENTS WITH ATRIAL FIBRILLATION. Variable Patients (n=7,459) Follow-up time, years 4 (2–7) Male sex 3,836 (51.4) Age in years 74 (65–82) <55 698 (9.4) 55–64 1,131 (15.2) 65–74 1,993 (26.7) 75–84 2,257 (30.3) ≥85 1,380 (18.5) CHA2DS2-VASc score 3 (2–4) CHA2DS2-VASc score ≥2 5,829 (78.1) Heart failure 1,250 (16.8) Hypertension 3,717 (49.8) Diabetes mellitus 1,497 (20.1) CVA or TIA 833 (11.2) Vascular diseasea 1,617 (21.7) Renal impairmentb 1,313 (17.6) Dementia 256 (3.4) Asthma or COPD 1,295 (17.4) Malignancyc 623 (8.4) History of bleedingd 1,407 (18.9) Antithrombotic therapy 5,667 (76.0) Beta blocker 4,680 (62.7) Calcium channel blocker 1,543 (20.7) Digoxin 1,451 (19.5) Data are median (interquartile range) or n (%). a Coronary artery disease or peripheral vascular (arterial or venous) disease. b International Classification of Primary Care (ICPC) code U99.01 (renal impairment) or estimated glomerular filtration rate <60 mL/min/1.73 m2. c Five most prevalent malignancies in the Netherlands (apart from skin cancer): breast cancer, prostate cancer, colon cancer, lung cancer, and haematological cancer. d Posttraumatic extradural/subdural/intracerebral haemorrhage, haemoptysis, epistaxis, haematemesis, melaena, haematochezia, haematuria, menorrhagia, postpartum haemorrhage. COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; n: number; TIA: transient ischaemic attack.
RkJQdWJsaXNoZXIy MTk4NDMw